Long-term virus-induced alterations of CYP3A-mediated drug metabolism: A look at the virology, immunology and molecular biology of a multi-faceted problem

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 10, 2009, Pages 1189-1211

  Croyle, Maria A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adaptive immune response; Cytochrome P450 3A; Drug metabolism; Innate immune response; Integrin receptors; Liver; Virus

Indexed keywords

16ALPHA CYANOPREGNENOLONE; ALPHA INTERFERON; BETA INTERFERON; CCAAT ENHANCER BINDING PROTEIN; CYTOCHROME P450 3A; DEXAMETHASONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTOXIN; PARACETAMOL; RANTES; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RIFAMPICIN; TAMOXIFEN; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS RECEPTOR; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADENOVIRUS; BIRD DISEASE; CELL CULTURE; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG METABOLISM; EPSTEIN BARR VIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INNATE IMMUNITY; LIVER; MOLECULAR BIOLOGY; MURINE LEUKEMIA; NONHUMAN; POLIOMYELITIS VIRUS; PROTEIN PROCESSING; RABIES VIRUS; REVIEW; RHINOVIRUS; ROTAVIRUS; SARS CORONAVIRUS; SEROTYPE; SIGNAL TRANSDUCTION; SMALLPOX VIRUS; VARICELLA ZOSTER VIRUS; VIROLOGY; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS RECOMBINANT; WART VIRUS; WEST NILE FLAVIVIRUS;

ANIMALS; CYTOCHROME P-450 CYP3A; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNITY, INNATE; LIVER; PHARMACEUTICAL PREPARATIONS; VIRUS DISEASES;

EID: 70349397608     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903136748     Document Type: Review

References (225)

1. Snowden FM. Emerging and reemerging diseases: a historical perspective. Immunol Rev 2008;225:9-26
2. Yang X, Yang H, Zhou G, Zhao GP. Infectious disease in the genomic era. Annu Rev Genomics Hum Genet 2008;9:21-48
3. Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008;451(7181):990-993 (Pubitemid 351301726)
4. Soto SM. Human migration and infectious diseases. Clin Microbiol Infect 2009;15(Suppl 1):26-28
5. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther 2009;17(5):767-777
6. Bouard D, Alazard-Dany N, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol 2009;2157(2):153-165
7. Beloqui A, de María PD, Golyshin PN, Ferrer M. Recent trends in industrial microbiology. Curr Opin Microbiol 2008;11(3):240-248
8. Kman NE, Nelson RN. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am 2008;26(2):517-547
9. Samaras SC, Dietz N. Physiopathology of dextoxification of pentobarbital sodium. Fed Am Soc Exp Biol 1953;12:122-5 •• This is the first scientific paper to describe changes in drug metabolism during inflammation.
10. Kato R, Nakamura Y, Chiesara E. Enhanced phenobarbital induction of liver microsomal drug-metabolizing enzymes in mice infected with murine hepatitus virus. Biochem Pharmacol 1963;12:365-70 •• This is the first scientific paper to describe changes in drug metabolism during virus infection.
11. Leeson GA, Biedenback SA, Chan KY, et al. Decrease in activity of the drug metabolizing enzymes of the rat following the administration of tilorone hydrochloride. Drug Metab Dispos 1976;4(3):232-8 •• This is one of the first scientific papers to correlate changes in drug metabolism during inflammation with changes in hepatic cytochrome P450 enzymes.
12. Renton KW, Mannering GJ. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem Biophys Res Commun 1976;73(2):343-8 •• This is one of the first scientific papers to correlate changes in drug metabolism during inflammation with changes in hepatic cytochrome P450 enzymes.
13. Singh G, Renton KW. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation. Mol Pharmacol 1981;20(3):681-684 (Pubitemid 12252294)
14. Renton KW. Depression of hepatic cytochrome P-450-dependent mixed function oxidases during infection with encephalomyocarditis virus. Biochem Pharmacol 1981;30(16):2333-2336
15. Chow HH, Tang Y, Li P, etal. The effect of chronic retrovirus infection and immune dysfunction on the P-450-mediated activation of acetaminophen in mouse liver microsomes. Biopharm Drug Dispos 1998;19(1):9-15
16. Meredith CG, Christian CD, Johnson RF, et al. Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 1985;37(4):396-401
17. Renton KW. Relationships between the enzymes of detoxication and host defense mechanisms. In: Caldwell J, Jacoby WB, editors, Biological Basis of Detoxication. New York: Academic Press; 1983. p. 307-324
18. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987;2(8565):939-941
19. Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994;55(6):649-660 (Pubitemid 24212266)
20. Gidal BE, Reiss WG, Liao JS, Pitterle ME. Changes in interleukin-6 concentrations following epilepsy surgery: potential influence on carbamazepine pharmacokinetics. Ann Pharmacother 1996;30(5):545-546
21. Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94(6):2209-2214 (Pubitemid 24379590)
22. Chang KC, Bell TD, Lauer BA, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978;1(8074):1132-3 •• This is the first clinical report describing significant changes in drug metabolism during adenovirus infection. (Pubitemid 8356442)
23. Reiss WG, Piscitelli SC. Drug-cytokine interactions: mechanisms and clinical implications. Biodrugs 1998;9(5):389-395 (Pubitemid 28216220)
24. Greenblatt DJ, He P, von Moltke LL, Court MH. The CYP3 Family. In: Ioannides C, editor, Cytochromes P450: role in the metabolism and toxicology of drugs and other xenobiotics. London: Royal Society of Chemistry; 2008. p. 354-372
25. Guengerich FP. Drug Metabolism as Catalyzed by Human Cytochrome P450 Enzymes. In: Sigel A, Sigel H, Siegel RKO, editors, The Unbiquitous Roles of Cytochrome P450 Proteins: Metal Ions in Life Sciences. Hoboken, NJ: Wiley; 2007. p. 561-584
26. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9(4):310-322
27. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104(1-3):1-8 (Pubitemid 26016371)
28. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-423 (Pubitemid 24229655)
29. Zhou SF, Xue CC, Yu XQ, etal. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29(6):687-710
30. Yoshinari K, Tien E, Negishi M, Honkakoski P. Receptor-Mediated Regulation of Cytochrome P450. In: Ioannides C, editor, Cytochromes P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics. London: Royal Society of Chemistry;2008. p. 418-439 •• Excellent review of nuclear receptors involved in regulation of cytochrome P450.
31. Plant N. The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 2007;1770(3):478-88 •• Excellent review of factors involved in regulation of cytochrome P450. (Pubitemid 46136752)
32. Lim YP, Kuo SC, Lai ML, Huang JD. Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction. Pharmacogenet Genomics 2009;19(1):11-24
33. Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006;34(5):756-764
34. Burk O, Arnold KA, Nussler AK, et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 2005;67(6):1954-1965 (Pubitemid 41007777)
35. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007;47(5):566-578
36. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56(6):1329-39 •• Early report describing the distal xenobiotic-responsive enhancer module in the CYP3A4 expression cassette.
37. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000;260(1-2):13-23
38. Martínez-Jiménez CP, Gómez-Lechón MJ, Castell JV, Jover R. Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol 2005;67(6):2088-101 •• Early report describing an extra distal enhancer module in the CYP3A4 expression cassette. (Pubitemid 41007791)
39. Martínez-Jiménez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007;8(2):185-94 •• Very comprehensive review describing the transcription factors and promoter/enhancer elements involved in regulation of CYP3A3 expression. (Pubitemid 46218685)
40. Kliewer SA, Moore JT, Wade L, etal. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92(1):73-82 •• This is the first paper to describe the cloning of PXR. The authors showed that PXR is expressed in the liver and the intestine, activated by PCN, glucocorticoids and binds to a response element that is conserved in CYP3A promoters. (Pubitemid 28053299)
41. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001;98(6):3369-74 •• This paper is one of the first to demonstrate that PXR is activated by toxic bile acids and is involved in their removal from the body. (Pubitemid 32220852)
42. Xie W, Radominska-Pandya A, Shi Y, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001;98(6):3375-80 •• This paper is one of the first to use knockout mice to find a direct link between PXR and CYP3A expression. (Pubitemid 32220853)
43. Westlind-Johnsson A, Malmebo S, Johansson A, etal. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003;31(6):755-61.
44. Westlind-Johnsson A, Malmebo S, Johansson A, Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003;31(6):755-761
45. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292(5525):2329-2333
46. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102(5):1016-1023
47. Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 2008;4(7):895-908
48. Fukuen S, Fukuda T, Matsuda H, et al. Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun 2002;298(3):433-438 (Pubitemid 35333725)
49. Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001;29(11):1454-1459 (Pubitemid 33000692)
50. Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 2004;279(47):49307-49314 (Pubitemid 39625817)
51. Wan YJ, An D, Cai Y, et al. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 2000;20(12):4436-44 •• This paper is one of the first to describe how PXR interacts with RXR to drive CYP expression.
52. Matsumura K, Saito T, Takahashi Y, et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene.Mol Pharmacol 2004;65(2):326-3334 •• This paper is one of the first to describe in detail how the RXR:PXR heterodimer interacts with the distal xenobiotic responsive enhancer molecule on the CYP3A promoter. (Pubitemid 38134260)
53. Pascussi JM, Drocourt L, Fabre JM, et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000;58(2):361-372 (Pubitemid 30497480)
54. Aouabdi S, Gibson G, Plant N. Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos 2006;34(1):138-144 (Pubitemid 43042655)
55. Ding X, Staudinger JL. Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther 2005;312(2):849-856 (Pubitemid 40189588)
56. Ding X, Staudinger JL. Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem Pharmacol 2005;69(5):867-873 (Pubitemid 40248628)
57. Lin W, Wu J, Dong H, etal. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem 2008;283(45):30650-30657
58. Pondugula SR, Brimer-Cline C, Wu J, et al. A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor. Drug Metab Dispos 2009;37(4):719-730
59. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008;283(15):9674-80 •• This paper is the first to identify a micro-RNA sequence that alters CYP3A4 expression.
60. Baes M, Gulick T, Choi HS, etal. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 1994;14(3):1544-52 •• This paper is the first to describe CAR and its interaction with RXR to drive gene expression. (Pubitemid 24074550)
61. Lamba JK, Lamba V, Yasuda K, et al. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther 2004;311(2):811-821 (Pubitemid 39391571)
62. Wei P, Zhang J, Egan-Hafley M, etal. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000;407(6806):920-3 •• This paper is the first to describe how CAR influences CYP expression and function. (Pubitemid 30794334)
63. Moore JT, Moore LB, Maglich JM, Kliewer SA. Functional and structural comparison of PXR and CAR. Biochim Biophys Acta 2003;1619(3):235-238
64. Yoshinari K, Kobayashi K, Moore R, et al. Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett 2003;548(1-3):17-20 •• This paper is the first to describe the mechanism by which CAR alters CYP expression and function. (Pubitemid 37281243)
65. Kobayashi K, Sueyoshi T, Inoue K, et al. Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 2003;64(5):1069-1075 (Pubitemid 37310739)
66. Choi HS, Chung M, Tzameli I, et al. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J Biol Chem 1997;272(38):23565-23571 (Pubitemid 27410926)
67. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001;41:123-143 (Pubitemid 32385885)
68. Maglich JM, Stoltz CM, Goodwin B, et al. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62(3):638-646 (Pubitemid 36329382)
69. Wei P, Zhang J, Dowhan DH, et al. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2002;2(2):117-126 (Pubitemid 34982215)
70. Pascussi JM, Robert A, Moreau A, et al. Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. Hepatology 2007;45(5):1146-1153 (Pubitemid 46775776)
71. Koike C, Moore R, Negishi M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 2007;71(5):1217-1221 (Pubitemid 46658675)
72. Woods CG, Heuvel JP, Rusyn I. Genomic profiling in nuclear receptor-mediated toxicity. Toxicol Pathol 2007;35(4):474-494 (Pubitemid 46911892)
73. Mangelsdorf DJ, Borgmeyer U, Heyman RA, etal. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 1992;6(3):329-344
74. Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam Horm 2007;75:1-32
75. Kopf E, Plassat JL, Vivat V, et al. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. J Biol Chem 2000;275(43):33280-33288 (Pubitemid 30808534)
76. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004;328:1-16 (Pubitemid 38352876)
77. Usui T, Saitoh Y, Komada F. Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull 2003;26(4):510-517
78. El-Sankary W, Bombail V, Gibson GG, Plant N. Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos 2002;30(9):1029-1034 (Pubitemid 34894656)
79. Pascussi JM, Drocourt L, Gerbal-Chaloin S, et al. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 2001;268(24):6346-6358 (Pubitemid 34014742)
80. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619(3):243-253
81. Tirona RG, Lee W, Leake BF, etal. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003;9(2):220-4 •• This paper is the first to describe the role of hepatocyte nuclear factors in CAR and PXR-mediated CYP expression and function. (Pubitemid 36227725)
82. Cheng PY, Wang M, Morgan ET. Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. J Pharmacol Exp Ther 2003;307(3):1205-1212 (Pubitemid 37494243)
83. Bombail V, Taylor K, Gibson GG, Plant N. Role of Sp1, C/EBP alpha, HNF3, and PXR in the basal- and xenobiotic-mediated regulation of the CYP3A4 gene. Drug Metab Dispos 2004;32(5):525-535 (Pubitemid 38535031)
84. Rodríguez-Antona C, Bort R, Jover R, et al. Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma.Mol Pharmacol 2003;63(5):1180-1189
85. Zídek Z, Anzenbacher P, Kmonícková E. Current status and challenges of cytokine pharmacology. Br J Pharmacol 2009;157(3):342-361
86. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36(2):205-16 •• Comprehensive review summarizing current research assessing the effect of cytokines in the context of many clinical applications on hepatic drug metabolism. (Pubitemid 351185732)
87. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007;35(9):1687-1693
88. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005;12(3):254-261 (Pubitemid 40825131)
89. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009;85(4):434-8 •• Excellent review summarizing current research in the area of microbial infection and hepatic drug metabolism.
90. Assenat E, Gerbal-Chaloin S, Larrey D, et al. Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 2004;40(4):951-960 (Pubitemid 39288129)
91. Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 2002;16(13):1799-1801
92. Gu X, Ke S, Liu D, etal. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 2006;281(26):17882-9 •• This is one of the first reports that ties changes in PXR-mediated CYP expression during infection to a major cell signaling pathway. (Pubitemid 44035587)
93. Staudinger JL, Lichti K. Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease. Mol Pharm 2008;5(1):17-34 (Pubitemid 351300031)
94. Pascussi JM, Dvorák Z, Gerbal-Chaloin S, et al. Pathophysiological factors affecting CAR gene expression. Drug Metab Rev 2003;35(4):255-268 (Pubitemid 38018105)
95. Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2004;2(1):4 •• This is one of the first reports that describes how RXR is affected by a certain cell signal transduction pathway during infection. (Pubitemid 40617881)
96. Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 2006;43(6):1202-1210 (Pubitemid 43980098)
97. Levitchi M, Fradette C, Bleau AM, et al. Signal transduction pathways implicated in the decrease in CYP1A1, 1A2 and 3A6 activity produced by serum from rabbits and humans with an inflammatory reaction. Biochem Pharmacol 2004;68(3):573-582 (Pubitemid 38887439)
98. Hylemon PB, Zhou H, Pandak WM, et al. Bile acids as regulatory molecules. J Lipid Res 2006 [Epub ahead of print]
99. Ghose R, White D, Guo T, et al. Regulation of hepatic drug-metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-interleukin 1 receptor domain-containing adaptor protein. Drug Metab Dispos 2008;36(1):95-101 •• This is one of the first reports that ties changes in hepatic CYP expression during infection to a toll-like receptor signaling pathway.
100. Zordoky BN, El-Kadi AO. Role of NF-kappaB in the regulation of cytochrome p450 enzymes. Curr Drug Metab 2009;10(2):164-178
101. Zhou C, Tabb MM, Nelson EL, et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 2006;116(8):2280-2289 (Pubitemid 44162338)
102. Zangar RC, Bollinger N, Verma S, et al. The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability. Mol Pharmacol 2008;73(6):1652-1658 (Pubitemid 351724354)
103. Zhu Y, Silverman RB. Revisiting heme mechanisms. A perspective on the mechanisms of nitric oxide synthase (NOS), Heme oxygenase (HO), and cytochrome P450s (CYP450s). Biochemistry 2008;47(8):2231-2243
104. Minamiyama Y, Takemura S, Imaoka S, etal. Irreversible inhibition of cytochrome P450 by nitric oxide. J Pharmacol Exp Ther 1997;283(3):1479-1485 (Pubitemid 28016524)
105. Lee CM, Pohl J, Morgan ET. Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 2009;37(4):865-872
106. Oesch-Bartlomowicz B, Oesch F. Phosphorylation of xenobiotic-metabolizing cytochromes P450. Anal Bioanal Chem 2008;392(6):1085-1092
107. Aguiar M, Masse R, Gibbs BF. Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev 2005;37(2):379-404 (Pubitemid 40677509)
108. Neve EP, Ingelman-Sundberg M. Intracellular transport and localization of microsomal cytochrome P450. Anal Bioanal Chem 2008;392(6):1075-1084
109. Correia MA, Sadeghi S, Mundo-Paredes E. Cytochrome P450 ubiquitination: branding for the proteolytic slaughter? Annu Rev Pharmacol Toxicol 2005;45:439-64 •• This is the first comprehensive review that discusses the limited number of studies studies that have assessed ubiquitination patterns of hepatic cytochrome P450.
110. Wang Y, Liao M, Hoe N, etal. A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation. J Biol Chem 2009;284(9):5671-5684
111. Wang X, Medzihradszky KF, Maltby D, Correia MA. Phosphorylation of native and heme-modified CYP3A4 by protein kinase C: a mass spectrometric characterization of the phosphorylated peptides. Biochemistry 2001;40(38):11318-26 •• This is one of the first studies that describes phosphorylation patterns of hepatic cytochrome P450. (Pubitemid 32911274)
112. Oesch-Bartlomowicz B, Oesch F. Cytochrome-P450 phosphorylation as a functional switch. Arch Biochem Biophys 2003;409(1):228-234
113. Hosseinpour F, Moore R, Negishi M, Sueyoshi T. Serine 202 regulates the nuclear translocation of constitutive active/androstane receptor. Mol Pharmacol 2006;69(4):1095-1102
114. Faouzi S, Medzihradszky KF, Hefner C, et al. Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97? Biochemistry 2007;46(26):7793-7803
115. Pabarcus MK, Hoe N, Sadeghi S, et al. CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys 2009;483(1):66-74
116. Chen M, Gerlier D. Viral hijacking of cellular ubiquitination pathways as an anti-innate immunity strategy. Viral Immunol 2005;19(3):349-362 (Pubitemid 44735049)
117. Dallaire F, Blanchette P, Groitl P, et al. Identification of Integrin {alpha}3 as a New Substrate of the Adenovirus E4orf6/E1B55K E3 Ubiquitin Ligase Complex. J Virol 2009;83(11):5329-5338
118. Ichikawa Y, Hiwatashi A. The role of the sugar regions of components of the cytochrome P-450-linked mixed-function oxidase (monooxygenase) system of bovine adrenocortical mitochondria. Biochim Biophys Acta 1982;705(1):82-91
119. Armstrong RN, Pinto-Coelho C, Ryan DE, et al. On the glycosylation state of five rat hepatic microsomal cytochrome P-450 isozymes. J Biol Chem 1983;258(4):2106-8 •• This describes the initial work on glycosylation of clinically relevant cytochrome P450 isoforms.
120. Amarneh B, Corbin CJ, Peterson JA, et al. Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis. Mol Endocrinol 1993;7(12):1617-1624 (Pubitemid 24034244)
121. Neu U, Stehle T, Atwood WJ. The Polyomaviridae: Contributions of virus structure to our understanding of virus receptors and infectious entry. Virology 2009;384(2):389-399
122. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009;19(3):165-178
123. Shors T. Virus Replication Cycles. Understanding Viruses Boston: Jones and Bartlett Publishers; 2009. p. 46-70
124. Carter J, Saunders V. Transcription, Translation and Transport. Virology: Principles and Applications. Hoboken, NJ: Wiley; 2007. p. 69-84
125. Netherton C, Moffat K, Brooks E, Wileman T. A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication. Adv Virus Res 2007;70:101-182
126. Wagner EK, Hewlett MJ, Bloon DC, Carmerini D. Human Immunodeficiency Virus Type I (HIV I) and Related Lentiviruses. Basic Virology. 3 edition. Malden, MA: Blackwell Publishing; 2008. p. 399-413
127. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134(1-2):235-249
128. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999;284(5418):1313-1318
129. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296(5566):298-300 (Pubitemid 34303673)
130. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003;3(2):169-176 (Pubitemid 37328694)
131. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol 2008;6(2):132-142
132. Tosi MF. Innate immune responses to infection. J Allergy Clin Immunol 2005;116(2):241-249
133. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344(14):1058-1066
134. Biron CA, Dalod M, Salazar-Mather TP. Innate Immunity and Viral Infections. In: Kaufman SHE, Sher A, Ahmed R, editors, Immunology of Infectious Diseases. Washington, D.C.: ASM Press;2002. p. 139-160
135. Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine 2008;43(3):336-341
136. Brandenburg B, Zhuang X. Virus trafficking - learning from single-virus tracking. Nat Rev Microbiol 2007;5(3):197-208 (Pubitemid 46291279)
137. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors.J Biochem 2007;141(2):137-145
138. Huang X, Yang Y. Innate immune recognition of viruses and viral vectors. Hum Gene Ther 2009;20(4):293-301
139. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16
140. Kato H, Takeuchim O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;41(7089):101-105 (Pubitemid 43827959)
141. Kato H, Sato S, Yoneyama M, etal. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005;23(1):19-28
142. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4(7):499-511
143. Hoshino K, Sugiyama T, Matsumoto M, et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006;440(7086):949-953
144. Uematsu S, Akira S. Toll-like receptors and Type I interferons. J Biol Chem 2007;282(21):15319-15323
145. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
146. Kawai T, Takahashi K, Sato S, etal. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005;6(10):981-988
147. Kawai T, Akira S. TLR Signaling. Cell Death Differ 2006;13:816-825
148. Richardson TA, Sherman M, Antonovic L, et al. Hepatic and renal cytochrome p450 gene regulation during citrobacter rodentium infection in wild-type and toll-like receptor 4 mutant mice. Drug Metab Dispos 2006;34(3):354-60 •• This is one of the first reports that ties changes in hepatic CYP expression during infection to a toll-like receptor signaling pathway. (Pubitemid 43290892)
149. Ghose R, Guo T, Haque N. Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid. Arch Biochem Biophys 2009;481(1):123-130
150. Chaluvadi MR, Nyagode BA, Kinloch RD, Morgan ET. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically
151. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003;10(11):935-940 (Pubitemid 36722427)
152. Bowen GP, Borgland SL, Lam M, et al. Adenovirus vector-induced inflammation:capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Hum Gene Ther 2002;13(3):367-379 (Pubitemid 34251502)
153. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol 1997;71(1):398-404 (Pubitemid 26412305)
154. Tamanini A, Nicolis E, Bonizzato A, et al. Interaction of adenovirus type5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 2006;80(22):11241- 11254 (Pubitemid 44706564)
155. Tibbles LA, Spurrell JC, Bowen GP, et al. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 2002;76(4):1559-1568
156. Szomolanyi-Tsuda E, Brehm MA, Welsh RM. Acquired Immunity Against Viral Infections. In: Kaufman SHE, Sher A, Ahmed R, editor, Immunology of Infectious Disease. Washington, D.C.: ASM Press; 2002. p. 247-265
157. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91 (Pubitemid 32368030)
158. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6(1):1-42 (Pubitemid 26096749)
159. Bogaards JJ, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000;30(12):1131-1152 (Pubitemid 32368013)
160. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-94 •• Comprehensive review describing species differences with respect to CYP-mediated drug metabolism. (Pubitemid 44911538)
161. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997;106(3):161-82 •• Useful reference that compares species differences of cytochome P450 activity in the context of catalytic activity and selectivity.
162. Muruganandan S, Sinal CJ. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ther 2008;83(6):818-28 •• Comprehensive review of mouse models currently used in drug metabolism research. (Pubitemid 351704925)
163. Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and invitro-invivo correlations. Xenobiotica 2007;37(10-11):1196-1224
164. Capecchi MR. The new mouse genetics: altering the genome by gene targeting. Trends Genet 1989;5(3):70-76
165. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, etal. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117(11):3583-92 •• Excellent summary of knockout mouse models for drug metabolism research. (Pubitemid 350097013)
166. Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008;327(2):288-99 •• Excellent summary of humanized mouse models for drug metabolism research.
167. Scheer N, Ross J, Rode A, etal. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 2008;118(9):3228-3239
168. Felmlee MA, Lon HK, Gonzalez FJ, Yu AM. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 2008;36(2):435-441
169. Ma X, Cheung C, Krausz KW, etal. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 2008;36(12):2506-2512
170. Dandri M, Burda MR, Török E, et al. Repopulation of mouse liver with human hepatocytes and invivo infection with hepatitis B virus. Hepatology 2001;33(4):981-8 •• First description of humanized mice with a clinically relevant application. (Pubitemid 32246649)
171. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7(8):927-933 (Pubitemid 32756430)
172. Tateno C, Yoshizane Y, Saito N, etal. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165(3):901-12 •• First description of using humanized mice to study drug metabolism. (Pubitemid 39129297)
173. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008;246(1):9-17
174. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 2008;10(2):391-400
175. Donato MT, Lahoz A, Castell JV, Gómez-Lechón MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008;9(1):1-11 (Pubitemid 351201665)
176. Hewitt NJ, Lechón MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39(1):159-234 •• Very complete review describing in vitro metabolism studies using primary hepatocytes.
177. Kojima K, Nagata K, Matsubara T, Yamazoe Y. Broad but distinct role of pregnane X receptor on the expression of individual cytochrome p450s in human hepatocytes. Drug Metab Pharmacokinet 2007;22(4):276-286
178. Clayton RF, Rinaldi A, Kandyba EE, et al. Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int 2005;25(2):389-402 (Pubitemid 40500575)
179. Hewitt NJ, Hewitt P. PhaseI and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2004;34(3):243-256 (Pubitemid 38478893)
180. Rodríguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32(6):505-20 •• This is one of the first manuscripts that describes the disparity between the expression and function patterns of cytochrome P450 in cell culture with respect to that observed in vivo. (Pubitemid 34743622)
181. Rencurel F, Stenhouse A, Hawley SA, et al. AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line. J Biol Chem 2005;280(6):4367-4373 (Pubitemid 41741356)
182. Gómez-Lechón MJ, Donato T, Jover R, et al. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem 2001;268(5):1448-1459 (Pubitemid 32231899)
183. Guillouzo A, Corlu A, Aninat C, etal. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007;168(1):66-73
184. McGinnity DF, Zhang G, Kenny J, et al. Evaluation of multiple invitro systems for assessment of CYP3A4 Induction in Drug Discovery: human hepatocytes, PXR reporter gene, Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009. [Epub ahead of print]
185. Hengstler JG, Brulport M, Schormann W, et al. Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol 2005;1(1):61-74
186. Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002;109(10):1291-1302 (Pubitemid 34546893)
187. Ruhnke M, Ungefroren H, Nussler A, et al. Differentiation of invitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology 2005;128(7):1774-1786 (Pubitemid 40824688)
188. Ehnert S, Nussler AK, Lehmann A, Dooley S. Blood monocyte-derived neohepatocytes as invitro test system for drug metabolism. Drug Metab Dispos 2008;36(9):1922-1929
189. Tuschl G, Lauer B, Mueller SO. Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin Drug Metab Toxicol 2008;4(7):855-870
190. Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007;168(1):16-29
191. Lim PL, Tan W, Latchoumycandane C, et al. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol InVitro 2007;21(8):1390-1401 (Pubitemid 350086855)
192. Castell JV, Gómez-Lechón MJ. Liver cell culture techniques. Methods Mol Biol 2009;481:35-46
193. Lake BG, Price RJ, Giddings AM, Walters DG. Invitro assays for induction of drug metabolism. Methods Mol Biol 2009;481:47-58 •• Excellent review for the novice that is considering using cell culture models for mechanistic study of drug metabolism.
194. Elaut G, Henkens T, Papeleu P, et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 2006;7(6):629-660 (Pubitemid 44234347)
195. Hansen LK, Wilhelm J, Fassett JT. Regulation of hepatocyte cell cycle progression and differentiation by type I collagen structure. Curr Top Dev Biol 2006;72:205-236
196. Shellie M. Callahan. Recombinant Adenoviral-Mediated Alterations of Cytochrome P450 3A2 and 2C11. Ph.D. dissertation, The Univeristy of Texas at Austin, 2005:128-165
197. Milosevic N, Schawalder H, Maier P. Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes. Eur J Pharmacol 1999;368:75-87 (Pubitemid 29106417)
198. Smedsrod B, Pertoft H. Preparation of pure hepatocytes and reticuloendothelial cells in high yield from a single rat liver by means of Percoll centrifugation and selective adherence. J Leukoc Biol 1985;38(2):213-230 (Pubitemid 15243425)
199. Castell JV, Jover R, Martonez-Jiménez CP, Gómez- Lechón MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006;2(2):183-212 (Pubitemid 46372364)
200. Persson KP, Ekehed S, Otter C, et al. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs invivo in humans. Pharm Res 2006;23(1):56-69 (Pubitemid 43214661)
201. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 2009;64(1):35-43
202. Kozawa M, Honma M, Suzuki H. Quantitative prediction of invivo profiles of CYP3A4 induction in humans from in vitro results with reporter gene assay. Drug Metab Dispos 2009;37(6):1234-1241
203. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-138
204. Schaffer DV, Koerber JT, Lim KI. Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 2008;10:169-194
205. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6(7):529-540 (Pubitemid 351850977)
206. Seemungal TA, Wedzicha JA. Viral infections in obstructive airway diseases. Curr Opin Pulm Med 2003;9(2):111-116
207. Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006;82(2S):S9-14 (Pubitemid 44126860)
208. Callahan SM, Ming X, Lu SK, et al. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J Pharmacol Exp Ther 2005;312(2):492-501 •• The first scientific paper describing a dose effect for a recombinant virus with respect to hepatic cytochrome P450 expression and function. (Pubitemid 40189545)
209. Callahan SM, Wonganan P, Croyle MA. Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. Virol J 2008;5:111 •• The first scientific paper that suggests that attenuation of the virus-induced immune response does not provide a similar change in drug metabolism patterns commonly seen during infection.
210. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002;13(15):1887-1900 (Pubitemid 35292683)
211. Croyle MA, Chirmule N, Zhang Y, Wilson JM. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001;75(10):4792-4801 (Pubitemid 32381522)
212. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007;36(1):71-80
213. Le HT, Boquet MP, Clark EA, etal. Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose. Hum Gene Ther 2006;17(11):1095-111 •• The first scientific paper describing a dose effect for a recombinant virus with respect to renal cytochrome P450 expression and function.
214. Callahan SM, Boquet MP, Ming X, et al. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. J Gene Med 2006;8(5):566-576 (Pubitemid 43827250)
215. Wonganan P, Zamboni WC, Strychor S, et al. Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Ther 2009;16(5):405-414
216. Suomalainen M, Nakano MY, Boucke K, et al. Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. EMBO J 2001;20(6):1310-1319 (Pubitemid 32233971)
217. Meier O, Greber U. Adenovirus endocytosis. J Gene Med 2003;5(6):451-462
218. Zimmerman TL, Thevananther S, Ghose R, etal. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem 2006;281(22):15434-15440 (Pubitemid 43855135)
219. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008;132(1-2):1-14 (Pubitemid 351232078)
220. Dupuy AG, Caron E. Integrin-dependent phagocytosis: spreading from microadhesion to new concepts. J Cell Sci 2008;121(Pt 11):1173-1183 (Pubitemid 351943370)
221. Greber UF. Signalling in viral entry. Cell Mol Life Sci 2002;59(4):608-626
222. Evans R, Patzak I, Svensson L, et al. Integrins in immunity. J Cell Sci 2009;122(Pt 2):212-225
223. Haüussinger D, Reinehr R, Schliess F. The hepatocyte integrin system and cell volume sensing. Acta Physiol 2006;187(1-2):249-255 (Pubitemid 43828783)
224. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009;122(Pt 2):159-163
225. Streuli CH, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J 2009;418(3):491-506